Veraxa Biotech (VRXA) investor relations material

Offering details and pricing

• F-1 registers resale by selling securityholders of up to 120,295,385 ordinary shares and 6,786,739 private warrants; preliminary prospectus dated July 31, 2026.

• Separately registers up to 19,436,739 shares issuable upon exercise of public and private warrants at $11.50 per share: 12,650,000 public-warrant shares and 6,786,739 private-warrant shares.

• High Trail financing includes a $27.5 million senior secured note and a warrant with $27.5 million aggregate exercise price; up to 11 million related shares are registered for resale.

• Lincoln Park committed to purchase up to $50 million of shares over 24 months at market-based prices, subject to conditions; 340,910 commitment shares issued July 30, 2026.

• 3.5 million shares issued to Cantor Fitzgerald & Co. on July 30, 2026, under the modified deferred-fee agreement; registered in the filing.

Risk factors and disclosures

• Swiss law limits indemnification for directors and executives who intentionally or grossly negligently breach duties; SEC views Securities Act indemnification as contrary to public policy and unenforceable.

• Other issuances under conditional capital reduce capacity for shares under the agreements; additional share capacity would require shareholder approval to amend the articles.

• Swiss counsel's validity opinion applies only when shares are issued, delivered, and paid for under the agreements, and relies on stated assumptions rather than independent fact verification.

Management team and governance

• Christoph Antz signed as CEO and director and is identified as board chair; Oliver Baumann is interim CFO and principal financial and accounting officer.

• Listed directors include Carl von Halem, Marc Grüninger, Warren Hosseinion, and Christoph Ziegler.

• Under Swiss law and the articles, shareholders may grant board members discharge for disclosed facts; other shareholders' right of action expires 12 months after the release resolution.